Better Health for All

UroGen Pharma's core business is focused on developing treatments for specialty cancers and urothelial diseases, with products like UGN-102 showing substantial health benefits, including an 82.3% duration of response at 12 months and a 79.6% complete response rate at 3 months in Phase 3 trials.

However, the company faces significant challenges in other areas. The list price for Jelmyto is $26,639.29 for one kit, though a copay program allows eligible patients to pay as little as $50 per dose with an annual benefit maximum of up to $14,000. A Patient Assistance Program (PAP) is available for patients with income at or below 400% of the Federal Poverty Level, but the reach to vulnerable populations is not quantified. The company offers patient education materials through UroGen Support. UroGen is facing a securities class action lawsuit alleging it misled investors about FDA concerns regarding the single-arm trial design for UGN-102, and an FDA advisory committee voted 5 to 4 against UGN-102, raising questions about risk transparency and clinical trial ethics. UroGen has a Comprehensive Compliance Program, including an annual aggregate dollar limit of $2,500 for items provided to California healthcare professionals, and provides periodic training to employees on ethical conduct.

Fair Money & Economic Opportunity

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for specialty cancers and urothelial diseases.

Its core activities are pharmaceutical research, development, and commercialization. The company does not engage in lending, insurance, or other financial services, nor does it offer financial products to consumers. Therefore, all KPIs related to fair money and economic opportunity are not applicable to its business operations.

Fair Pay & Worker Respect

For 2021, the CEO-to-median employee pay ratio was 22:1, with the CEO's total compensation at $4,212,666 and median employee compensation at $191,462.

Employee engagement is reflected by 65% of employees who would recommend working there. The employer pays 90% of health insurance costs, implying 100% of the workforce has employer-funded health insurance.

Fair Trade & Ethical Sourcing

No specific, concrete data points were found in the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing. The articles discuss internal corporate ethics, compliance programs, and financial performance, but do not provide information on fair-trade certifications, supplier audit frequencies, forced/child labor incidents, supply chain traceability, remediation speed for supplier violations, ethical clause coverage in supplier contracts, materials risk index, or supplier diversity spend.

General statements about expecting suppliers to uphold ethical standards or conducting internal audits do not provide the specific quantitative evidence required by the rubric's KPIs.

Honest & Fair Business

UroGen Pharma Ltd. has a 'Whistleblower Protection and Non-Retaliation Policy' (Corporate Policy 3040), amended September 13, 2024.

This policy explicitly prohibits retaliation and allows anonymous reporting through multiple channels, including a toll-free hotline, email, and a dedicated website. The company provides periodic training to employees and mentions the use of internal or external investigators for claims. The company has adopted an insider trading policy and a hedging policy. It also has a 'Corporate Code of Ethics and Conduct' and an 'Anti-Corruption Policy' (Corporate Policy 3010) as part of its Comprehensive Compliance Program (CCP). The CCP includes written standards, a compliance hotline, and auditing and monitoring activities. Periodic training is provided to employees, and the policy covers all markets, but customization for high-risk areas is not specified. The company's independent directors met five times in executive sessions during 2024. All directors except one are independent, meaning 87.5% of the board is independent (7 out of 8 directors). The company's audit committee pre-approves all audit, audit-related, and permitted non-audit services. The company has not had any financial restatements in the past five years, only minor disclosure tweaks. The company mentions the use of internal or external investigators to investigate claims, but the extent of independent verification of ethical claims is not specified beyond this.

Kind to Animals

No specific, concrete evidence was found across the provided articles to assess UroGen Pharma Ltd. against the 'Kind to Animals' ethical value. The articles primarily focus on general business ethics, compliance, and financial reporting, with no explicit details on animal welfare practices, animal testing policies or volumes, cruelty-free certifications, or investments in animal-free alternatives.

Therefore, no KPIs can be scored based on the provided information.

Planet-Friendly Business

UroGen Pharma Ltd. sourced 22.6% of its operational energy consumption from renewables in 2024, representing a year-over-year increase of 6.1%.

The company does not report any carbon emissions data or specify reduction targets. Its DitchCarbon score is 20, which is higher than 75% of companies in the Health Services industry. Sustainalytics assigned the company a High ESG Risk Rating of 36.1, ranking it 642 out of 847 in the Pharmaceuticals industry.

Safe & Smart Tech

UroGen Pharma provides periodic security training for all employees, including initial training for new hires and annual training for existing employees.

The company's privacy policy grants users rights to access, rectify, and delete their data, object to processing, request data transfer, and opt-out of marketing. Data is retained for 5 years or until no longer needed for legitimate business purposes. The company is committed to ethical standards and compliance with applicable laws, specifically noting compliance with California Health and Safety Code §§ 119400-119402, and submits an annual declaration of compliance.